Yhdysvallat - englanti - NLM (National Library of Medicine)

denton pharma, inc. dba northwind pharmaceuticals - diclofenac potassium (unii: l4d5ua6cb4) (diclofenac - unii:144o8ql0l1) - carefully consider the potential benefits and risks of diclofenac potassium tablets and other treatment options before deciding to use diclofenac potassium tablets. use the lowest effective dose for the shortest duration consistent with individual patient treatment goals (see warnings: gastrointestinal bleeding, ulceration, and perforation). diclofenac potassium tablets are indicated: - for treatment of primary dysmenorrhea - for relief of mild to moderate pain - for relief of the signs and symptoms of osteoarthritis - for relief of the signs and symptoms of rheumatoid arthritis diclofenac potassium tablets are contraindicated in the following patients: - known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac or any components of the drug product (see warnings: anaphylactic reactions, serious skin reactions). - history of asthma, urticaria, or allergic-type reactions after taking aspirin or other nsaids. severe, sometimes fat

Malta - englanti - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 850 mg - drugs used in diabetes

Malta - englanti - Medicines Authority

kern pharma, s.l. polígono industrial colón ii calle venus 72 08228, terrassa, barcelona , spain - film-coated tablet - sitagliptin 50 mg metformin hydrochloride 1000 mg - drugs used in diabetes

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

pharma-q holdings (pty) ltd - #n/a - not indicated - none

Etelä-Afrikka - englanti - South African Health Products Regulatory Authority (SAHPRA)

pharma-q holdings (pty) ltd - #n/a - not indicated - none

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 100 mg - tablet, uncoated - excipient ingredients: lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a; hypromellose - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; lactose monohydrate; microcrystalline cellulose; magnesium stearate; sodium starch glycollate type a - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Australia - englanti - Department of Health (Therapeutic Goods Administration)

southern cross pharma pty ltd - amisulpride, quantity: 400 mg - tablet, uncoated - excipient ingredients: sodium starch glycollate type a; hypromellose; microcrystalline cellulose; magnesium stearate; lactose monohydrate - amisulpride is indicated for the treatment of acute and chronic schizophrenic disorders, in which positive symptoms (such as delusions, hallucinations, thought disorders) and/or negative symptoms (such as blunted affect, emotional and social withdrawal) are prominent, including patients characterised by predominant negative symptoms.

Euroopan unioni - englanti - EMA (European Medicines Agency)

mylan s.a.s. - pregabalin - anxiety disorders; neuralgia; epilepsy - antiepileptics, - epilepsypregabalin mylan pharma is indicated as adjunctive therapy in adults with partial seizures with or without secondary generalisation.generalised anxiety disorderpregabalin mylan pharma is indicated for the treatment of generalised anxiety disorder (gad) in adults.

Malesia - englanti - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

idaman pharma manufacturing sdn bhd - diazepam -